Compare Consolidated Edison, Inc. (ED) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs Summit Therapeutics Inc — how do they compare? Consolidated Edison, Inc. trades at $107.65 (market cap $39.76B), while Summit Therapeutics Inc trades at $15.52 (market cap $12.06B). The key difference: Consolidated Edison, Inc. is far larger — about 3.3× Summit Therapeutics Inc's market cap, and Consolidated Edison, Inc. pays a 3.27% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ED | SMMT | |
|---|---|---|
Market Cap | $39.76B | $12.06B |
Sector | Utilities | Health |
52-Week High | $115.46 | $26.98 |
52-Week Low | $95.37 | $12.55 |
Enterprise Value | $66.61B | $11.39B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $106.3, down 1.56% today, near the consensus price target of $103.25. Recent Q2 2026 earnings beat estimates with EPS of $0.83, though Q1 missed. The stock shows a bearish technical trend with support at $105 and resistance at $108. Fundamentals are stable with 2025 revenue of $16.92B and net income margin of 12.53%, supported by consistent dividend payments.
ED offers steady income with a 3.2% dividend yield and regulated utility stability, but faces headwinds from high debt levels and mixed analyst sentiment (62.96% hold rating). Key risks include interest rate sensitivity and capital expenditure demands for grid upgrades. The stock suits defensive investors seeking reliable dividends amid moderate growth expectations.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
